These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21921189)

  • 21. Structural analysis of human and macaque mAbs 2909 and 2.5B: implications for the configuration of the quaternary neutralizing epitope of HIV-1 gp120.
    Spurrier B; Sampson JM; Totrov M; Li H; O'Neal T; Williams C; Robinson J; Gorny MK; Zolla-Pazner S; Kong XP
    Structure; 2011 May; 19(5):691-9. PubMed ID: 21565703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16.
    Pancera M; Shahzad-Ul-Hussan S; Doria-Rose NA; McLellan JS; Bailer RT; Dai K; Loesgen S; Louder MK; Staupe RP; Yang Y; Zhang B; Parks R; Eudailey J; Lloyd KE; Blinn J; Alam SM; Haynes BF; Amin MN; Wang LX; Burton DR; Koff WC; Nabel GJ; Mascola JR; Bewley CA; Kwong PD
    Nat Struct Mol Biol; 2013 Jul; 20(7):804-13. PubMed ID: 23708607
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population-based analysis of HIV-1 antibodies reveals structural constraints that may inform vaccine design.
    Tobin SC
    AIDS; 2015 Sep; 29(15):N13. PubMed ID: 26237101
    [No Abstract]   [Full Text] [Related]  

  • 24. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.
    Wu X; Yang ZY; Li Y; Hogerkorp CM; Schief WR; Seaman MS; Zhou T; Schmidt SD; Wu L; Xu L; Longo NS; McKee K; O'Dell S; Louder MK; Wycuff DL; Feng Y; Nason M; Doria-Rose N; Connors M; Kwong PD; Roederer M; Wyatt RT; Nabel GJ; Mascola JR
    Science; 2010 Aug; 329(5993):856-61. PubMed ID: 20616233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design.
    Bonsignori M; Montefiori DC; Wu X; Chen X; Hwang KK; Tsao CY; Kozink DM; Parks RJ; Tomaras GD; Crump JA; Kapiga SH; Sam NE; Kwong PD; Kepler TB; Liao HX; Mascola JR; Haynes BF
    J Virol; 2012 Apr; 86(8):4688-92. PubMed ID: 22301150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Roles of glycans in interactions between gp120 and HIV broadly neutralizing antibodies.
    Qi Y; Jo S; Im W
    Glycobiology; 2016 Mar; 26(3):251-60. PubMed ID: 26537503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.
    Doria-Rose NA; Schramm CA; Gorman J; Moore PL; Bhiman JN; DeKosky BJ; Ernandes MJ; Georgiev IS; Kim HJ; Pancera M; Staupe RP; Altae-Tran HR; Bailer RT; Crooks ET; Cupo A; Druz A; Garrett NJ; Hoi KH; Kong R; Louder MK; Longo NS; McKee K; Nonyane M; O'Dell S; Roark RS; Rudicell RS; Schmidt SD; Sheward DJ; Soto C; Wibmer CK; Yang Y; Zhang Z; ; Mullikin JC; Binley JM; Sanders RW; Wilson IA; Moore JP; Ward AB; Georgiou G; Williamson C; Abdool Karim SS; Morris L; Kwong PD; Shapiro L; Mascola JR
    Nature; 2014 May; 509(7498):55-62. PubMed ID: 24590074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid and Focused Maturation of a VRC01-Class HIV Broadly Neutralizing Antibody Lineage Involves Both Binding and Accommodation of the N276-Glycan.
    Umotoy J; Bagaya BS; Joyce C; Schiffner T; Menis S; Saye-Francisco KL; Biddle T; Mohan S; Vollbrecht T; Kalyuzhniy O; Madzorera S; Kitchin D; Lambson B; Nonyane M; Kilembe W; ; ; Poignard P; Schief WR; Burton DR; Murrell B; Moore PL; Briney B; Sok D; Landais E
    Immunity; 2019 Jul; 51(1):141-154.e6. PubMed ID: 31315032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Construction and phenotypic characterization of HIV type 1 functional envelope clones of subtypes G and F.
    Revilla A; Delgado E; Christian EC; Dalrymple J; Vega Y; Carrera C; González-Galeano M; Ocampo A; de Castro RO; Lezaún MJ; Rodríguez R; Mariño A; Ordóñez P; Cilla G; Cisterna R; Santamaría JM; Prieto S; Rakhmanova A; Vinogradova A; Ríos M; Pérez-Álvarez L; Nájera R; Montefiori DC; Seaman MS; Thomson MM
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):889-901. PubMed ID: 21226626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. INFECTIOUS DISEASES. Designer proteins produce potent HIV defense.
    Cohen J
    Science; 2015 Jun; 348(6241):1297. PubMed ID: 26089490
    [No Abstract]   [Full Text] [Related]  

  • 31. An HIV-1 envelope immunogen with W427S mutation in CD4 binding site induced more T follicular helper memory cells and reduced non-specific antibody responses.
    Yu HT; Tian D; Wang JY; Guo CX; Li Y; Wang X; Li D; Zhang FM; Zhuang M; Ling H
    PLoS One; 2014; 9(12):e115047. PubMed ID: 25546013
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monoclonal antibody m18 paratope leading to dual receptor antagonism of HIV-1 gp120.
    Gift SK; McFadden K; Zentner IJ; Rajagopal S; Zhang MY; Dimitrov DS; Chaiken IM
    Biochemistry; 2011 Apr; 50(14):2769-79. PubMed ID: 21417283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody 2G12 recognizes di-mannose equivalently in domain- and nondomain-exchanged forms but only binds the HIV-1 glycan shield if domain exchanged.
    Doores KJ; Fulton Z; Huber M; Wilson IA; Burton DR
    J Virol; 2010 Oct; 84(20):10690-9. PubMed ID: 20702629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes.
    Martin L; Stricher F; Missé D; Sironi F; Pugnière M; Barthe P; Prado-Gotor R; Freulon I; Magne X; Roumestand C; Ménez A; Lusso P; Veas F; Vita C
    Nat Biotechnol; 2003 Jan; 21(1):71-6. PubMed ID: 12483221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of gp120 and its single-chain derivatives, gp120-CD4D12 and gp120-M9: implications for targeting the CD4i epitope in human immunodeficiency virus vaccine design.
    Varadarajan R; Sharma D; Chakraborty K; Patel M; Citron M; Sinha P; Yadav R; Rashid U; Kennedy S; Eckert D; Geleziunas R; Bramhill D; Schleif W; Liang X; Shiver J
    J Virol; 2005 Feb; 79(3):1713-23. PubMed ID: 15650196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Germlining of the HIV-1 broadly neutralizing antibody domain m36.
    Chen W; Li W; Ying T; Wang Y; Feng Y; Dimitrov DS
    Antiviral Res; 2015 Apr; 116():62-6. PubMed ID: 25676867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. B cell antigenic site mapping of HIV-1 glycoproteins.
    Neurath AR
    Chem Immunol; 1993; 56():34-60. PubMed ID: 8452653
    [No Abstract]   [Full Text] [Related]  

  • 38. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites.
    Kwong PD; Doyle ML; Casper DJ; Cicala C; Leavitt SA; Majeed S; Steenbeke TD; Venturi M; Chaiken I; Fung M; Katinger H; Parren PW; Robinson J; Van Ryk D; Wang L; Burton DR; Freire E; Wyatt R; Sodroski J; Hendrickson WA; Arthos J
    Nature; 2002 Dec; 420(6916):678-82. PubMed ID: 12478295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted deletion in the beta20-beta21 loop of HIV envelope glycoprotein gp120 exposes the CD4 binding site for antibody binding.
    Berkower I; Patel C; Ni Y; Virnik K; Xiang Z; Spadaccini A
    Virology; 2008 Aug; 377(2):330-8. PubMed ID: 18519142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complementary and synergistic activities of anti-V3, CD4bs and CD4i antibodies derived from a single individual can cover a wide range of HIV-1 strains.
    Ramirez Valdez KP; Kuwata T; Maruta Y; Tanaka K; Alam M; Yoshimura K; Matsushita S
    Virology; 2015 Jan; 475():187-203. PubMed ID: 25486586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.